Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ГУ Институт неврологии, психиатрии и наркологии Национальной академии медицинских наук Украины, Харьков
Список исп. литературыСкрыть список 1. Addington J, Epstein I, Liu L et al. A randomizedcontrolled trial of cognitive behavioral therapy for individuals at clinical high riskof psychosis. Schizophr Res 2011; 125: 54–61. 2. Amminger GP, Schäfer MR, Papageorgiou K et al. Long-Chain {omega}-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry 2010; 67 (2): 146–54. 3. Bechdolf A, Wagner M, Ruhrmann S et al. Preventing progression to first-episode psychosis in early initial prodromal states. Br J Psychiatry 2012; 200: 22–9. Update: Contemp Clin Trials 28 (2): 105–14. 4. McGorry P, van Os J. Redeeming diagnosis in psychiatry: timing versus specificity. Lancet 2013; 381 (9863): 343–5. 5. McGorry PD, Nelson B, Phillips LJ et al. Randomized controlled trial of interventions for young people at ultra-high risk ofpsychosis: Twelve-month outcome. J Clin Psychiatry 2013; 74 (4): 349–56. 6. McGorry PD, Yung AR, Phillips LJ et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry 2002; 59 (10): 921–8. 7. Van der Gaag M, Smit F, Bechdolf A et al. Prevention a first episode of psychosis: Meta-analysis of randomized controlled prevention trials of 12 month and longer-term follow-ups. Schizophr Res 2013; 149: 56–62. 8. Adams CE, Fenton MKP, Quraishi S, David AS. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 2001; 179: 290–9. 9. Leucht C et al. Oral versus depot antipsychotic drugs for schizophrenia. Schizophr Res 2011; 127: 83–92. 10. Nitta M, Kishimoto T, Müller N et al. Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials. Schizophr Bull 2013; 39: 1230–41. 11. McGlashan TH, Zipursky RB, Perkins D et al. Randomized, double-blind trial of olanzapine versus placebo in patientsprodromally symptomatic for psychosis. Am J Psychiatry 2006; 163 (5): 790–9. 12. Morrison P, French P, Stewart SLK et al. Early detection and intervention evaluation for people at risk of psychosis: multisite randomised controlled trial. BMJ 2012; 344 (1): e2233. 13. Preti A, Cella M. Randomized-controlled trials in people at ultra high risk of psychosis: a review of treatment effectiveness. Schizophr Res 2010; 123: 30–6. 14. Morrison AP, French P, Parker S et al. Three-year follow-up of a randomized controlled trial of cognitive therapy forthe prevention of psychosis in people at ultrahigh risk. Schizophr Bull 2007; 33 (3): 682–7. 15. Morrison AP, French P, Walford L et al. Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial. Br J Psychiatry 2004; 185: 291–7. 16. Van der Gaag M, Nieman H, Rietdijk J et al. Cognitive behavioral therapy for subjects at ultrahigh risk for developingpsychosis: a randomized controlled clinical trial. Schizophr Bull 2012; 38 (6): 1180–8. 17. Wykes T, Steel C, Everitt B, Tarrier N. Cognitive behavior therapy for schizophrenia: effect sizes, clinical models, and methodological rigor. Schizophr Bull 2008; 34 (3): 523–37. 18. Nordentoft M, Thorup A, Petersen L et al. Transition rates from schizotypal disorder to psychotic disorder for first-contact patients included in the OPUS trial. A randomized clinical trial of integrated treatment and standard treatment. Schizophr Res 2006; 83 (1): 29–40.